Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of TQB2102 for recurrent/metastatic advanced gynecologic tumors
CTR20250493Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in gynecological cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
TQB2102
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on CTR20250493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250493.